I am not an expert when it comes to FTDs but mostly that won't be awarded after a ph1 or ph1b and with more patients' data needed. That way it is remarkable to get this after just 4, or actually just 3 patients' data available. Dr Litten has been praised by Jennifer Chow and Dr Bec for his clever trial design and dealing with the FDA. Maybe he together with Dr Bec should do the raising talks, pretty sure the outcome wouldn't be as bad as they have been over the past 3 years. RAD got the endorsement by Lantheus in their radiotreatment field, hasn't helped the sp but at least opened the tap for " unlimited " funding. IMO, if there is still a place for a CAR-T to attack solid cancers, especially in the gastric and brain field, then there must be someone out there to provide the funding. If not, and CAR-Ts are seen as either outdated or not commercially viable by the big players then even a FTD won't help. And the problem for us retailers is now to do the research, finding out what role CAR-Ts will place in the future of oncology as we get mixed signals. The FDA and clinicians say YES, but the fund providers as well as insurers and Trump's Admin say NO due to the immense treatment costs. And the same applies to IMU with its Azer-Cel CAR-T.
GLTA
CHM Price at posting:
0.5¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)